News
-
CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced a license and collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors. Under the terms of the agreement, CoImmune is acquiring rights …
-
CoImmune, Inc. to Participate in Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced that Charles Nicolette, chief executive officer of CoImmune, will present a corporate update on September 23, 2021 at 9:05AM EDT during the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Dr. Nicolette will review progress in …
-
CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors
CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company’s board of directors. Dr. Baracchini brings a wealth of biotechnology industry and financial expertise, as well as significant prior board level experience, to …
CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors Read More »
-
CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy by principal investigator Andrea Biondi, M.D. and …
-
Business Wire
Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, and CoImmune, Inc. (“CoImmune”), a privately held clinical-stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, announced today that the companies have entered into a license agreement for ITI to use CoImmune’s proprietary dendritic cell process for certain ITI cell therapy vaccine programs. The partnership highlights the oncology pipeline of ITI and CoImmune’s expertise and technology in the development and manufacture of cell-based therapeutics.
-
CoImmune, Inc. Announces Closing of $45 Million Series A Financing
CoImmune, Inc., an immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the closing of a $45M Series A financing. CoImmune will use the proceeds from the financing to fund its ongoing Phase 2b trial for lead asset, CMN-001, in advanced renal cell carcinoma and multiple …
CoImmune, Inc. Announces Closing of $45 Million Series A Financing Read More »
-
CoImmune, Inc. today announced that it has successfully completed the merger with Formula Pharmaceuticals, Inc., bringing together two therapeutic immuno-oncology platforms. Formula Pharmaceuticals merged into CoImmune with CoImmune as the surviving company. CoImmune will continue to focus on running a Phase 2b trial for lead asset, CMN-001, in advanced renal cell carcinoma. With the merger’s …
-
CoImmune, Inc. announced today that the FDA approved its investigational new drug application (IND) and that it is cleared to move forward with a Phase 2b clinical trial in advanced metastatic renal cell carcinoma (mRCC). CMN-001, formerly known as AGS-003, is a dendritic cell-based immunotherapy custom matched to each patient’s particular disease. The rationale for …
